KIP Infrastructure
2.12.0 - ci-build
KIP Infrastructure, published by Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S. This guide is not an authorized publication; it is the continuous build for version 2.12.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/KIP-infrastructure/implementation-guide/ and changes regularly. See the Directory of published versions
| Official URL: https://kip.rkkp.dk/fhir/ValueSet/ATCChemoPreparation | Version: 2.12.0 | |||
| Active as of 2022-06-14 | Computable Name: ATCChemoPreparation | |||
ATC koder for præparater for kemobehandling
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
This value set includes codes based on the following rules:
https://kip.rkkp.dk/fhir/CodeSystem/ATC| Code | Display | Definition |
| L01BC02 | Fluorouracil (5-FU) | L01BC02 - Fluorouracil (5-FU) |
| L01BC05 | Gemcitabine | L01BC02 - Gemcitabine |
| L01BC06 | Capecitabine | L01BC06 - Capecitabine |
| L01CA04 | Vinorelbine | L01CA04 - Vinorelbine |
| L01CD01 | Paclitaxel | L01CD01 - Paclitaxel |
| L01CD02 | Docetaxel | L01CD02 - Docetaxel |
| L01CE02 | Irinotecan | L01CE02 - Irinotecan |
| L01DB01 | Doxorubicin | L01DB01 - Doxorubicin |
| L01DB03 | Epirubicin | L01DB03 - Epirubicin |
| L01FD01 | Trastuzumab | L01FD01 - Trastuzumab |
| L01FF01 | Nivolumab | L01FF01 - Nivolumab |
| L01FF02 | Pembrolizumab | L01FF02 - Pembrolizumab |
| L01FG01 | Bevacizumab | L01FG01 - Bevacizumab |
| L01XA01 | Cisplatin | L01XA01 - Cisplatin |
| L01XA02 | Carboplatin | L01XA02 - Carboplatin |
| L01XA03 | Oxaliplatin | L01XA03 - Oxaliplatin |
| S01LA08 | Bevacizumab | S01LA08 - Bevacizumab |
https://kip.rkkp.dk/fhir/CodeSystem/GenericValues
| Code | Display | Definition |
| other | Andet | Other - used to choose unspecific value not in a valueset |
Expansion performed internally based on:
This value set contains 18 concepts
| Code | System | Display | Definition |
| L01BC02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Fluorouracil (5-FU) | L01BC02 - Fluorouracil (5-FU) |
| L01BC05 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Gemcitabine | L01BC02 - Gemcitabine |
| L01BC06 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Capecitabine | L01BC06 - Capecitabine |
| L01CA04 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Vinorelbine | L01CA04 - Vinorelbine |
| L01CD01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Paclitaxel | L01CD01 - Paclitaxel |
| L01CD02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Docetaxel | L01CD02 - Docetaxel |
| L01CE02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Irinotecan | L01CE02 - Irinotecan |
| L01DB01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Doxorubicin | L01DB01 - Doxorubicin |
| L01DB03 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Epirubicin | L01DB03 - Epirubicin |
| L01FD01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Trastuzumab | L01FD01 - Trastuzumab |
| L01FF01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Nivolumab | L01FF01 - Nivolumab |
| L01FF02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Pembrolizumab | L01FF02 - Pembrolizumab |
| L01FG01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Bevacizumab | L01FG01 - Bevacizumab |
| L01XA01 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Cisplatin | L01XA01 - Cisplatin |
| L01XA02 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Carboplatin | L01XA02 - Carboplatin |
| L01XA03 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Oxaliplatin | L01XA03 - Oxaliplatin |
| S01LA08 | https://kip.rkkp.dk/fhir/CodeSystem/ATC | Bevacizumab | S01LA08 - Bevacizumab |
| other | https://kip.rkkp.dk/fhir/CodeSystem/GenericValues | Andet | Other - used to choose unspecific value not in a valueset |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |